For Rigel, a surprising placebo response spurs a PhIII fail, stock beating. But it's been here before
A California biotech familiar with speed bumps ran into another early Wednesday as it tries to push its only approved drug into another indication. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
